Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ATP-sensitive potassium (KATP) channel complex is a hetero-octameric protein assembly that serves as a metabolic sensor, coupling cellular energy status to membrane excitability. It is composed of four pore-forming inwardly rectifying potassium channel subunits (Kir6.1 or Kir6.2) and four regulatory sulfonylurea receptor subunits (SUR1 or SUR2). In vascular smooth muscle and endothelial cells, the Kir6.1/SUR2B isoform predominates, where its activation causes hyperpolarization and vasodilation, thereby regulating blood pressure and regional blood flow (UniProt P48048, O60706). In the central nervous system, KATP channels in neurons and astrocytes (typically Kir6.2/SUR1) provide neuroprotection during metabolic stress, such as ischemia, by hyperpolarizing the membrane to reduce energy consumption and prevent excitotoxicity (PubMed 16443510). Mutations in the genes encoding these subunits, such as KCNJ8 and ABCC9, are associated with conditions like Cantu syndrome and cardiovascular dysfunction (NIH, 2023). Pharmacological agents include KATP openers like minoxidil and diazoxide, which are used for hypertension and hypoglycemia, respectively (PubChem, 2024). Conversely, KATP blockers like glibenclamide are used in the treatment of diabetes and are being investigated for their role in reducing brain edema following stroke (StatPearls, 2023).
The KATP channel complex functions as a metabolic sensor that couples the intracellular ATP/ADP ratio to membrane potential. Binding of ATP to the Kir6.x subunits inhibits the channel, while binding of Mg-ADP to the SUR subunits promotes opening. Channel openers (e.g., minoxidil, diazoxide) stabilize the open state, causing potassium efflux and hyperpolarization, which leads to vasodilation in vascular tissues or reduced excitability in neurons. Channel blockers (e.g., sulfonylureas) inhibit the channel, leading to depolarization and increased cellular activity (Nichols, 2006; StatPearls, 2023).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-sensitive potassium channel complex (KATP) (KATP).